No. 1858 Yinzhongnan Road
Guoxiang Subdistrict Wuzhong District
Suzhou
China
https://www.ocumension.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 444
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Ye Liu | CEO & Executive Director | 763k | S.O. | 1972 |
Dr. Zhaopeng Hu | Chief Development Officer & Executive Director | 283,61k | S.O. | 1974 |
Mr. Tim Ruan | CFO & Joint Company Secretary | S.O. | S.O. | 1986 |
Dr. DongHong Chen | Chief Medical Officer | S.O. | S.O. | 1971 |
Mr. Qinglei Zuo | Chief Commercial Officer | S.O. | S.O. | 1984 |
Ms. Tingchan Chen | Joint Company Secretary | S.O. | S.O. | 1995 |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
L’ISS Governance QualityScore de Ocumension Therapeutics en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..